Early vedolizumab trough levels at induction in inflammatory bowel disease patients with treatment failure during maintenance.

Background Vedolizumab (VDZ) is effective as an induction and maintenance treatment for Crohn's disease and ulcerative colitis, but, as observed with antitumour necrosis factor-a (anti-TNFa) agents, some patients are nonetheless experiencing loss of response. Objective The aim of this study was to investigate the impact of the pharmacokinetics of VDZ during induction on long-term treatment response. Patients and methods This study focused on a single cohort of 103 inflammatory bowel disease patients treated with VDZ. VDZ trough levels (TLs) were measured by enzyme-linked immunosorbent assay (n = 536 samples), and thereafter correlated to clinical, biological, endoscopic and serological data. For patients exposed previously to infliximab, antibodies to infliximab were measured at baseline. On the basis of the outcome at the end of follow-up, patients were then categorized into long-term response, optimized and treatment failure groups. Results During VDZ induction, at week 6, inflammatory bowel disease patients with long-term response had higher TLs compared with patients in the treatment failure group (33 vs. 24 mu g/ml, P = 0.02). A cut-off TL of 28 mu g/ml predicted a sustained response in the follow-up with an area under curve of 0.723 (95% confidence interval = 0.567-0.878, P = 0.02). Patients with mucosal healing in maintenance had higher TLs at week 6 (41.65 mu g/ml) compared with patients with mild (26 mu g/ml) or severe endoscopic activity (20.8 mu g/ml), P = 0.009. Positive perinuclear antineutrophil cytoplasmic antibody serology was associated with lower TLs. Patients previously exposed to anti-TNFa had lower TLs than naive patients (22.5 vs. 36 mu g/ml, P = 0.03) without any impact of detectable antibodies to infliximab. Finally, the presence of an immunomodulator at induction did not impact on VDZ TLs at induction. Conclusion We confirmed that a drug exposure-efficacy association was found early on at induction. This study emphasizes that previous exposure to anti-TNFa and positive perinuclear antineutrophil cytoplasmic antibody serology are important factors influencing VDZ TLs at induction. Copyright (C) 2019 Wolters Kluwer Health, Inc. All rights reserved.